AGES:LSE:LSE-iShares IV Public Limited Company - iShares Ageing Population UCITS ETF (GBX)

ETF | Others |

Last Closing

USD 562.125

Change

0.00 (0.00)%

Market Cap

USD 0.47B

Volume

9.07K

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-05-05 )

Largest Industry Peers for Others

Symbol Name Price(Change) Market Cap
XMTD:LSE Xtrackers MSCI Taiwan UCITS ET..

N/A

USD 292,109.19B
0R15:LSE SoftBank Group Corp.

N/A

USD 9,217.80B
0R1E:LSE Nintendo Co. Ltd.

N/A

USD 7,596.04B
0R1O:LSE Amazon.com Inc.

N/A

USD 1,607.29B
LCJP:LSE Lyxor Core MSCI Japan (DR) UCI..

N/A

USD 642.91B
LCJD:LSE Amundi MSCI Japan (DR) UCITS E..

N/A

USD 636.40B
0R1I:LSE NVIDIA Corp.

N/A

USD 618.20B
0R1G:LSE Home Depot Inc.

N/A

USD 373.16B
XDJP:LSE Xtrackers Nikkei 225 UCITS ETF..

N/A

USD 330.91B
0QZK:LSE Coca-Cola Co.

N/A

USD 266.08B

ETFs Containing AGES:LSE

N/A

Market Performance

  Market Performance vs. Industry/Classification (Others) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 2.48% 44% F 49% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 2.48% 43% F 49% F
Trailing 12 Months  
Capital Gain 6.67% 45% F 54% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 6.67% 44% F 53% F
Trailing 5 Years  
Capital Gain 27.28% 49% F 61% D-
Dividend Return N/A N/A N/A N/A N/A
Total Return 27.28% 46% F 57% F
Average Annual (5 Year Horizon)  
Capital Gain 5.08% 55% F 60% D-
Dividend Return 5.08% 54% F 59% D-
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 13.33% 55% F 69% C-
Risk Adjusted Return 38.12% 58% F 70% C-
Market Capitalization 0.47B 69% C- 59% D-

Annual Financials (GBX)

Quarterly Financials (GBX)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:

There is nothing we particularly dislike